US Pharma MarketingThe post ThalassaX doses first US patient in Phase I study of CS231295 appeared first on Clinical Trials Arena.
ThalassaX doses first US patient in Phase I study of CS231295
ThalassaX Therapeutics United States has dosed the first patient in its Phase I trial of CS231295, a brain-penetrant Aurora B kinase selective inhibitor. The post ThalassaX doses first US patient in Phase I study of CS231295 appeared first on Clinical Trials Arena .
ThalassaX Therapeutics United States has dosed the first patient in its Phase I trial of CS231295, a brain-penetrant Aurora B kinase selective inhibitor.
Source: Clinical Trials Arena